Ciclopiroxolamine: clinical and microbiological considerations. Preliminary data.
Ciclopiroxolamine's action has been evaluated in 20 cases of dermatophytosis. The minimum inhibitory concentrations (MIC) for the strains was determined in vitro before treatment (To), after the 4th day (T4), and after the 7th day (T7) of treatment, in relation with the drug's fungicide effect. No significant variation was observed among the MIC values. By comparing the MIC of T4 versus the MIC of To a 0.93 coefficient of linear correlation was obtained while in comparing T7 versus T4 the coefficient was equivalent to 1.0. After 7 days of treatment 5 patients clinically recovered, 11 improved and 4 showed no improvement. Drug tolerance was excellent except for one case.
D003883:Arthrodermataceae / Q000187:drug effects; D000077768:Ciclopirox; D003881:Dermatomycoses / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D011728:Pyridones / Q000494:pharmacology / Q000627:therapeutic use*
D011728:Pyridones; D000077768:Ciclopirox